Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2012-04-17

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm300087jPMID 22468757
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches

  2013cited by this paper
• Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

  2012cited by this paper
• Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.

  2012cited by this paper
• Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

  2012cited by this paper
• Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands.

  2012cited by this paper
• Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists.

  2011cited by this paper
• Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers.

  2011cited by this paper
• The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists.

  2011cited by this paper
• CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver

  2011cited by this paper
• Differential Roles of GSK-3&bgr; During Myocardial Ischemia and Ischemia/Reperfusion

  2011cited by this paper
• Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.

  2011cited by this paper
• Pyrazolo Derivatives as Potent Adenosine Receptor Antagonists: An Overview on the Structure-Activity Relationships

  2011cited by this paper
• Adenosine and ATP receptors in the brain.

  2011cited by this paper
• A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release

  2011cited by this paper
• Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway

  2011cited by this paper
• International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

  2011cited by this paper
• Regio- and stereoselective synthesis of truncated 3'-aminocarbanucleosides and their binding affinity at the A3 adenosine receptor.

  2011cited by this paper
• Colocalization and Regulated Physical Association of Presynaptic Serotonin Transporters with A3 Adenosine Receptors

  2011cited by this paper
• Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.

  2011cited by this paper
• Does the combination of optimal substitutions at the C²-, N⁵- and N⁸-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A₃ adenosine receptors?

  2011cited by this paper
• Recent developments in adenosine receptor ligands and their potential as novel drugs.

  2011cited by this paper
• Adenosine receptor targeting in health and disease

  2011cited by this paper
• QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.

  2011cited by this paper
• A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway.

  2011cited by this paper
• New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.

  2011cited by this paper
• A1 Receptors Ligands: Past, Present and Future Trends

  2010cited by this paper
• Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes

  2010cited by this paper
• Adenosine receptors as drug targets.

  2010cited by this paper
• Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.

  2010cited by this paper
• Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development.

  2010cited by this paper
• The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor.

  2010cited by this paper
• The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells.

  2010cited by this paper
• A3 Adenosine Receptor Antagonists: History and Future Perspectives

  2010cited by this paper
• Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor.

  2010cited by this paper
• Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors.

  2010cited by this paper
• The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.

  2010cited by this paper
• Adenosine Modulates HIF-1&agr;, VEGF, IL-8, and Foam Cell Formation in a Human Model of Hypoxic Foam Cells

  2010cited by this paper
• Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists.

  2010cited by this paper
• Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.

  2010cited by this paper
• A2A adenosine receptor overexpression and functionality, as well as TNF‐α levels, correlate with motor symptoms in Parkinson's disease

  2010cited by this paper
• A3 receptor ligands: past, present and future trends.

  2010cited by this paper
• The role of adenosine receptors in rheumatoid arthritis.

  2010cited by this paper
• Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species.

  2010cited by this paper
• 2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists.

  2010cited by this paper
• Molecular modeling study on potent and selective adenosine A(3) receptor agonists.

  2010cited by this paper
• 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.

  2009cited by this paper
• A3 adenosine receptor: pharmacology and role in disease.

  2009cited by this paper
• A1 adenosine receptor antagonists, agonists, and allosteric enhancers.

  2009cited by this paper
• Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

  2009cited by this paper
• Adenosine A3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity

  2009cited by this paper
• The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease.

  2009cited by this paper
• Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.

  2009cited by this paper
• Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.

  2009cited by this paper
• Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists.

  2009cited by this paper
• Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor.

  2009cited by this paper
• Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

  2009cited by this paper
• A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor.

  2009cited by this paper
• Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate.

  2009cited by this paper
• Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

  2009cited by this paper
• Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts.

  2009cited by this paper
• Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies.

  2009cited by this paper
• Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

  2009cited by this paper
• Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor.

  2009cited by this paper
• Divergent solution-phase synthesis of diarylpyrimidine libraries as selective A3 adenosine receptor antagonists.

  2009cited by this paper
• Cl‐IB‐MECA enhances TRAIL‐induced apoptosis via the modulation of NF‐κB signalling pathway in thyroid cancer cells

  2009cited by this paper
• Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor.

  2008cited by this paper
• Selective Human Adenosine A3 Antagonists based on Pyrido[2,1‐f]purine‐2,4‐diones: Novel Features of hA3 Antagonist Binding

  2008cited by this paper
• A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis.

  2008cited by this paper
• The adenosine kinase hypothesis of epileptogenesis.

  2008cited by this paper
• Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility.

  2008cited by this paper
• Cyclic adenosine 5′-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients

  2008cited by this paper
• Synthesis of 3′-Acetamidoadenosine Derivatives as Potential A3 Adenosine Receptor Agonists

  2008cited by this paper
• Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.

  2008cited by this paper
• Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease – clinical relevance and pathophysiological mechanisms

  2008cited by this paper
• Activation of the A3 Adenosine Receptor Suppresses Superoxide Production and Chemotaxis of Mouse Bone Marrow Neutrophils

  2008cited by this paper
• Synthesis and pharmacological characterization of [125I]MRS1898, a high-affinity, selective radioligand for the rat A3 adenosine receptor

  2008cited by this paper
• Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000

  2008cited by this paper
• OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

  2008cited by this paper
• The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways.

  2008cited by this paper
• Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.

  2008cited by this paper
• The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

  2008cited by this paper
• Structure-activity relationship studies of a new series of imidazo[2,1-f]purinones as potent and selective A(3) adenosine receptor antagonists.

  2008cited by this paper
• Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.

  2008cited by this paper
• Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.

  2008cited by this paper
• Synthesis of 2-chloro-N6-substituted-4'-thioadenosine-5'-N, N-dialkyluronamides as potent and selective A3 adenosine receptor antagonists.

  2008cited by this paper
• Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists.

  2008cited by this paper
• Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.

  2008cited by this paper
• Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists.

  2008cited by this paper
• Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields.

  2008cited by this paper
• Design and synthesis of truncated 4'-thioadenosine derivatives as potent and selective A3 adenosine receptor antagonists.

  2008cited by this paper
• The A3 adenosine receptor: an enigmatic player in cell biology.

  2008cited by this paper
• Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration.

  2007cited by this paper
• Adenosine as a modulator of brain activity.

  2007cited by this paper
• Design, synthesis, and biological evaluation of LNA nucleosides as adenosine A3 receptor ligands.

  2007cited by this paper
• Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor

  2007cited by this paper
• Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: Focus on the A3 adenosine subtype

  2007cited by this paper
• Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.

  2007cited by this paper
• 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.

  2007cited by this paper
• [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor.

  2007cited by this paper
• New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

  2007cited by this paper

• Structural Simplification from Tricyclic to Bicyclic Scaffolds: A Long-Term Investigation in the Field of Adenosine Receptor Antagonists

  2025cites this paper
• Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor

  2024cites this paper
• Synthesis and Biological Evaluation of 5'-Deoxy-adenosine Derivatives as A3 Adenosine Receptor Ligands.

  2024cites this paper
• Stereochemical influence of 4'-methyl substitutions on truncated 4'-thioadenosine derivatives: Impact on A3 adenosine receptor binding and antagonism.

  2024cites this paper
• Structure-Activity Relationship of Truncated 4'-Selenonucleosides: A3 Adenosine Receptor Activity and Binding Selectivity.

  2024cites this paper
• Problems and prospects for finding new pharmacological agents among adenosine receptor agonists, antagonists, or their allosteric modulators for the treatment of cardiovascular diseases.

  2023cites this paper
• C2‐linked alkynyl poly‐ethylene glycol(PEG) adenosine conjugates as water‐soluble adenosine receptor agonists

  2022cites this paper
• Adenosine, Adenosine Receptors and Neurohumoral Syncope: From Molecular Basis to Personalized Treatment

  2022cites this paper
• Molecular Simulations and Drug Discovery of Adenosine Receptors

  2022cites this paper
• Dual A1/A3 Adenosine Receptor Antagonists: Binding Kinetics and Structure-Activity Relationship Studies Using Mutagenesis and Alchemical Binding Free Energy Calculations.

  2022cites this paper
• Machine Learning for Discovery of New ADORA Modulators

  2022cites this paper
• Application of diazonium chemistry in purine modifications: A focused review

  2021cites this paper
• A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.

  2021cites this paper
• Agonists and Antagonists for Purinergic Receptors.

  2020cites this paper
• Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases

  2020influential citation
• Recent Advances of In-Silico Modeling of Potent Antagonists for the Adenosine Receptors.

  2019cites this paper
• Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity.

  2019cites this paper
• Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs).

  2019cites this paper
• A 2A Adenosine Receptor: Structures, Modeling, and Medicinal Chemistry

  2018cites this paper
• Discovery of benzothiazolylquinoline conjugates as novel human A3 receptor antagonists: biological evaluations and molecular docking studies

  2018cites this paper
• Probing structure‐activity relationship in &bgr;‐arrestin2 recruitment of diversely substituted adenosine derivatives

  2018cites this paper
• A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy

  2018cites this paper
• Safety issues of compounds acting on adenosinergic signalling

  2017cites this paper
• Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors

  2017cites this paper
• Adenosine contribution to normal renal physiology and chronic kidney disease.

  2017cites this paper
• Effect of Nitrogen Atom Substitution in A3 Adenosine Receptor Binding: N-(4,6-Diarylpyridin-2-yl)acetamides as Potent and Selective Antagonists.

  2017cites this paper
• Structure–Affinity Relationships and Structure–Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists

  2017cites this paper
• N6-Substituted 5'-N-Methylcarbamoyl-4'-selenoadenosines as Potent and Selective A3 Adenosine Receptor Agonists with Unusual Sugar Puckering and Nucleobase Orientation.

  2017cites this paper
• Cytokinin Nucleosides - Natural Compounds with a Unique Spectrum of Biological Activities.

  2016cites this paper
• Rhodium(III)‐Catalysed Carbenoid C(sp2)–H Functionalisation of Aniline Substrates with α‐Diazo Esters: Formation of Oxindoles and Characterisation/Utility of an Intermediate‐Like Rhodacycle

  2016cites this paper
• The synthesis of a series of adenosine A3 receptor agonists.

  2016cites this paper
• Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor.

  2016cites this paper
• One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists.

  2015cites this paper
• Navigating in chromone chemical space: discovery of novel and distinct A3 adenosine receptor ligands

  2015cites this paper
• The A3 Adenosine Receptor: History and Perspectives

  2015cites this paper
• History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents

  2015cites this paper
• The Literature of Heterocyclic Chemistry, Part XIII, 2012–2013

  2015cites this paper
• John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors☆

  2014cites this paper
• Adenosine and inflammation: what's new on the horizon?

  2014cites this paper
• Hyperbranched polyester nanorods with pyrrolo[2,1-a]isoquinoline end groups for fluorescent recognition of Fe3+

  2014cites this paper
• Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor.

  2014cites this paper
• Synthesis and Anti-Renal Fibrosis Activity of Conformationally Locked Truncated 2-Hexynyl-N6-Substituted-(N)-Methanocarba-nucleosides as A3 Adenosine Receptor Antagonists and Partial Agonists

  2014cites this paper
• Regioselective and efficient synthesis of N7-substituted adenines, guanines, and 6-mercaptopurines

  2013cites this paper
• Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches.

  2013cites this paper
• Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold.

  2013cites this paper
• Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.

  2013cites this paper
• A novel multicomponent microwave-assisted synthesis of 5-aza-adenines

  2013cites this paper
• Adenosine receptors as drug targets — what are the challenges?

  2013cites this paper
• Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists

  2012cites this paper